160 related articles for article (PubMed ID: 35896257)
1. Experience With Tirabrutinib in the Treatment of Primary Central Nervous System Lymphoma that Is Difficult to Treat With Standard Treatment.
Yoshioka H; Okuda T; Nakao T; Fujita M; Takahashi JC
Anticancer Res; 2022 Aug; 42(8):4173-4178. PubMed ID: 35896257
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Kitagawa J; Aoi A; Nishikawa R
Neuro Oncol; 2021 Jan; 23(1):122-133. PubMed ID: 32583848
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
4. Experience with nasogastric tube administration of tirabrutinib in the treatment of an elderly patient with primary central nervous system lymphoma.
Yoshioka H; Okuda T; Nakao T; Fujita M; Takahashi JC
Int Cancer Conf J; 2021 Oct; 10(4):290-293. PubMed ID: 34567940
[TBL] [Abstract][Full Text] [Related]
5. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
Nagane M
Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
[TBL] [Abstract][Full Text] [Related]
6. Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
Kim N; Lim DH; Yoon SE; Kim SJ; Kim WS
J Neurooncol; 2021 Sep; 154(2):207-217. PubMed ID: 34331673
[TBL] [Abstract][Full Text] [Related]
7. Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma.
Holdhoff M; Mrugala MM; Grommes C; Kaley TJ; Swinnen LJ; Perez-Heydrich C; Nayak L
J Natl Compr Canc Netw; 2020 Nov; 18(11):1571-1578. PubMed ID: 33152700
[TBL] [Abstract][Full Text] [Related]
8. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
9. Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib.
Arakawa Y; Narita Y; Nagane M; Mishima K; Terui Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Aoi A; Nishikawa R
Neurooncol Adv; 2023; 5(1):vdad109. PubMed ID: 37744697
[TBL] [Abstract][Full Text] [Related]
10. Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma.
Okita Y; Kano-Fujiwara R; Nakatsuka SI; Honma K; Kinoshita M
Exp Hematol Oncol; 2021 Apr; 10(1):29. PubMed ID: 33902692
[TBL] [Abstract][Full Text] [Related]
11. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
[TBL] [Abstract][Full Text] [Related]
12. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
[TBL] [Abstract][Full Text] [Related]
13. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
Sasaki N; Nagane M
No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
[TBL] [Abstract][Full Text] [Related]
14. Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.
Yonezawa H; Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Aoi A; Nishikawa R
Neurooncol Adv; 2024; 6(1):vdae037. PubMed ID: 38690230
[TBL] [Abstract][Full Text] [Related]
15. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
[TBL] [Abstract][Full Text] [Related]
16. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
[TBL] [Abstract][Full Text] [Related]
17. Continuous intrathecal injection therapy of methotrexate is a therapeutic option in primary CNS lymphoma.
Otani R; Yamada R; Kushihara Y; Inazuka M; Shinoura N
J Clin Neurosci; 2019 Nov; 69():26-30. PubMed ID: 31466902
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
[TBL] [Abstract][Full Text] [Related]
19. Tirabrutinib maintenance therapy for a patient with high-dose methotrexate-ineligible primary central nervous system lymphoma.
Okamura T; Hosoi H; Matsufusa T; Akagi Y; Iwamoto R; Kosako H; Murata S; Mushino T; Murata SI; Sonoki T
Ann Hematol; 2022 Jun; 101(6):1379-1381. PubMed ID: 35083523
[No Abstract] [Full Text] [Related]
20. Advances and challenges in the treatment of primary central nervous system lymphoma.
Yang H; Xun Y; Yang A; Liu F; You H
J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
